NASDAQ · MDCX
Medicus Pharma Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MDCX: Nov 13, 2026
Medicus Pharma Ltd. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-8.5. The reported EPS for the same quarter last year was $-32.5.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-8.50 | $-8.00 | $-9.00 | 2 |
| Dec 2026 | $-6.50 | $-5.50 | $-7.50 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel- RTTNews · Oct 26, 9:16 AM EDTMedicus Pharma Regains Nasdaq Compliance After Meeting Minimum Share Price Requirement(RTTNews) – Medicus Pharma (MDCX) announced that it has regained compliance with Nasdaq's minimum bid price requirement, resolving a listing-related compliance issue for the biotechnology company. Medicus said it received written notification from Nasdaq on October 23 confirming
- Fintel · Oct 22, 9:27 PM EDTMedicus Pharma Consensus Price Target Increased by 4,427.78% to $207.82The average one-year price target for Medicus Pharma (NASDAQCM:MDCX) has been revised to $207.82 / share, up from $4.59 dated September 29, 2026 — an increase of 4,427.78%. These figures represent aggregate analyst targets and do not constitute a recommendation by Fintel.Th
- RTTNews · Oct 8, 10:41 AM EDTMedicus Charts Multi-Asset Growth Strategy After Three Years Of Expansion; Stock Down(RTTNews) – Medicus Pharma (MDCX) marked its third anniversary as a public company by highlighting its transformation into a precision oncology-focused biotechnology company and outlining a strategy aimed at building long-term value through advancement of multiple therapeutic pro
- RTTNews · Sep 29, 9:26 AM EDTMedicus Pharma Advances Teverelix Into Streamlined Phase 2b/3 Design(RTTNews) – Medicus Pharma (MDCX), on Tuesday, said it submitted a streamlined Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (FDA) for Teverelix in advanced prostate cancer patients at increased cardiovascular risk.
- RTTNews · Sep 29, 9:21 AM EDTMedicus Pharma Files Phase 2b/3 Trial Design For Teverelix(RTTNews) – Tuesday, Medicus Pharma (MDCX) submitted a streamlined Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer patients at increased cardiovascular risk.
- RTTNews · Sep 22, 10:09 AM EDTMedicus Pharma Narrows SkinJect Focus To Gorlin Syndrome, Drops Sporadic BCC Program(RTTNews) – Medicus Pharma Ltd. (MDCX) announced that it will focus future internally sponsored clinical development of SkinJect exclusively on patients with Gorlin syndrome and multiple basal cell carcinoma (BCC) lesions, while concluding further development in sporadic/nodular
- RTTNews · Sep 4, 2:08 AM EDTMedicus Posts Wider Loss In Q2 Due To Higher Expenses; Stock Up(RTTNews) – Medicus Pharma Ltd. (MDCX), a clinical-stage biotech company, reported second quarter results showing a wider loss due to higher expenses, mainly associated with operating and interest expenses.
- RTTNews · Aug 3, 12:04 PM EDTMedicus Appoints Mehmud CEO Of UK Unit Antev, Replacing Interim CEO Kholi; Stock Up(RTTNews) – Medicus Pharma Ltd. (MDCX) on Monday announced the appointment of Faisal Mehmud as Chief Executive Officer (CEO) of its U.K. subsidiary, Antev Limited, effective August 30, 2026.
- RTTNews · Aug 3, 2:42 AM EDTMedicus Secures United Arab Emirates DOH Authorization For Phase 2a Teverelix Trial In Endometriosis(RTTNews) – Medicus Pharma Ltd. (MDCX) announced that the Department of Health (DOH) – Abu Dhabi has granted Investigational New Drug (IND) authorization, for the Phase 2a PRECISION-E2 genomics-enabled trial to evaluate Teverelix in women with symptomatic endometriosis in the Uni
- RTTNews · Jul 29, 6:08 AM EDTMedicus To Continue Phase 2 For SkinJect In Carcinoma With FDA Recommendations; Stock Falls 12%(RTTNews) – Medicus Pharma Inc. (MDCX), a biotech/life sciences company, on Tuesday announced the receipt of a 'Study May Proceed' notification from the U.S. Food and Drug Administration (FDA), allowing for the initiation of the Phase 2b SKNJCT-005 trial evaluating SkinJect in Go
- RTTNews · Jul 16, 9:19 AM EDTMedicus Pharma Receives Positive FDA Feedback For Optimized Phase 2 Study Of Teverelix In AUR(RTTNews) – Medicus Pharma Ltd. (MDCX) announced that it has reveived written feedback from the FDA and central Institutional Review Board approval for its redesigned Phase 2 clinical study of Teverelix in men following a first episode of acute urinary retention. The regulatory a
- RTTNews · Jun 16, 2:43 AM EDTMedicus Pharma Submits FDA Rare Pediatric Designation For SkinJect In Gorlin Syndrome(RTTNews) – Medicus Pharma Ltd. (MDCX) on Monday announced the submission of a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration for SkinJect for the treatment of basal cell carcinoma in patients with Gorlin Syndrome.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Medicus Pharma Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.